Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Jochen K. Lennerz"'
Autor:
Enrico Moiso, Alexander Farahani, Hetal D. Marble, Austin Hendricks, Samuel Mildrum, Stuart Levine, Jochen K. Lennerz, Salil Garg
Publikováno v:
Cancer Discov
Cancer is partly a developmental disease, with malignancies named based on cell or tissue of origin. However, a systematic atlas of tumor origins is lacking. Here we map the single-cell organogenesis of 56 developmental trajectories to the transcript
Autor:
Kristen Spencer, Leontios Pappas, Islam Baiev, Jordan Maurer, Andrea Grace Bocobo, Karen Zhang, Apurva Jain, Anaemy Danner De Armas, Stephanie Reyes, Tri Minh Le, Osama E Rahma, Jennifer Stanton, Thomas T DeLeon, Marc Roth, Mary Linton B Peters, Andrew X Zhu, Jochen K Lennerz, A John Iafrate, Kylie Boyhen, Christine VanCott, Lewis R Roberts, Stacie Lindsey, Nora Horick, Laura Williams Goff, Kabir Mody, Mitesh J Borad, Rachna T Shroff, Robin Kate Kelley, Milind M Javle, Lipika Goyal
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in
Autor:
Martha B. Pitman, Jochen K. Lennerz, Eric M. Przybyszewski, Matthew W. Rosenbaum, David G. Forcione, Joseph Misdraji, Kumar Krishnan, Daniel S. Pratt, Anthony J. Iafrate, Kyle Staller, Johannes F. Scheid
Publikováno v:
Cancer Cytopathology. 130:215-230
Background Primary sclerosing cholangitis (PSC) is a well-described risk factor for the development of cholangiocarcinoma (CCA). Early detection of CCA in these patients is of great importance because it expands options for therapeutic interventions,
Autor:
Colin D. Weekes, James C. Cusack, Christine E. Eyler, Lipika Goyal, Jochen K. Lennerz, Emily E. Van Seventer, Jill N. Allen, Jennifer Y. Wo, Peter J. Ulintz, Andrew X. Zhu, Hui Zheng, Susan G.R. McDuff, Theodore S. Hong, Daniel Kim, David P. Ryan, Mehlika Hazar-Rethinam, Jeffrey W. Clark, Ryan B. Corcoran, Isobel J Fetter, Brandon Nadres, Lawrence S. Blaszkowsky, Aparna Raj Parikh, Karin M. Hardiman
Publikováno v:
JCO Precis Oncol
PURPOSE This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC). MATERIALS AND METHODS Twen
Autor:
Laura Spring, Barbara L. Smith, Jochen K. Lennerz, Veerle Bossuyt, Ibiayi Dagogo-Jack, Leif W. Ellisen, Loren Winters, Lesli A. Kiedrowski, Alphonse G. Taghian, Zehra Ordulu, Aditya Bardia, Lindsey Mortensen
Publikováno v:
Oncologist
Enhanced understanding of the molecular events underlying oncogenesis has led to the development of “tumor‐agnostic” treatment strategies, which aim to target a tumor's genomic profile regardless of its anatomic site of origin. A classic exampl
Autor:
Ibiayi Dagogo-Jack, Russell W. Madison, Jochen K. Lennerz, Kuei-Ting Chen, Julia F. Hopkins, Alexa B. Schrock, Lauren L. Ritterhouse, Ashley Lester, Keith A. Wharton Jr, Mari Mino-Kenudson, Natalie Danziger, Yin P. Hung, Douglas A. Mata, Jeffrey S. Ross
Publikováno v:
JCO Precision Oncology.
PURPOSE Mesothelioma is an aggressive malignancy with heterogeneous outcomes that are partly driven by the differential efficacy of existing therapies across histologic types and sites of origin. Large-scale molecular analysis of mesothelioma and its
Autor:
Harshabad Singh, Kristen E. Lowder, Kevin Kapner, Ronan J. Kelly, Hui Zheng, Nadine J. McCleary, Thomas A. Abrams, Jennifer A. Chan, Eileen M. Regan, Samuel J. Klempner, Alison M. Hannigan, Lauren K. Brais, Elizabeth A. Andrews, Matthew B. Yurgelun, James M. Cleary, Douglas A. Rubinson, Lauren L. Ritterhouse, Garrett E. Maron, Andrew J. Aguirre, Lu Tan, Pan Du, Jeffrey A. Meyerhardt, Emma Gardecki, Jochen K. Lennerz, Shidong Jia, Brian M. Wolpin, Peter C. Enzinger
Publikováno v:
Cancer Research. 83:CT155-CT155
Introduction: Preclinical studies suggest cooperativity between blocking the human epidermal growth factor receptor 2 (HER2) and the vascular endothelial growth factor (VEGF) pathways in gastroesophageal adenocarcinomas (GEAs). Methods:Patients with
Autor:
Alice T. Shaw, Jochen K. Lennerz, Rebecca S. Heist, Justin F. Gainor, Kelly Goodwin, Andrew Do, Philicia Moonsamy, Ibiayi Dagogo-Jack, Aaron N. Hata, Subba R. Digumarthy, Inga T. Lennes, Zofia Piotrowska, Kristin Price, Sara Stevens, Alona Muzikansky, Jessica J. Lin, Lecia V. Sequist
Publikováno v:
Journal of Thoracic Oncology. 16:850-859
Introduction Capmatinib is approved for MET exon 14–altered NSCLC on the basis of activity in targeted therapy–naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor.
Autor:
Islam Baiev, Jochen K. Lennerz, Lesli A. Kiedrowski, Mohammed Usman Syed, Chendi Li, Rebecca S. Heist, Samuel J. Klempner, Dejan Juric, Aaron N. Hata, Mustafa Sakhi, Katerina A. Fella, Ryan B. Corcoran, Alexa G. Michel, Justin F. Gainor, Junbing Zhang, Liron Bar-Peled, Jessica J. Lin, Meagan B. Ryan, Noritaka Tanaka, Giulia Siravegna
Publikováno v:
Cancer Discovery. 11:1913-1922
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma